Formulation and in vitro evaluation of highly dispersive insulin dry powder formulations for lung administration

2010 ◽  
Vol 76 (3) ◽  
pp. 454-463 ◽  
Author(s):  
Flore Depreter ◽  
Karim Amighi
2012 ◽  
Vol 61 (1) ◽  
pp. 149-154 ◽  
Author(s):  
Gen Tamura ◽  
Hirokazu Sakae ◽  
Satoshi Fujino

2011 ◽  
Vol 5 (4) ◽  
Author(s):  
Nichakorn Sukasame ◽  
Narumon Nimnoo ◽  
Tan Suwandecha ◽  
Teerapol Srichana

AbstractBackground: Salbutamol is a βObjective: Evaluate the relationship of in vitro particle size characteristics and pharmacodynamics of formulations of inhaled salbutamol dry powder.Methods: Three formulations contained micronized salbutamol and a lactose carrier with different size ranges (40- 80, 20-40, and 10-20 μm for formulations 1, 2, and 3, respectively). Following formulation of the drug, resultant powders were characterized using scanning electron microscopy and the aerosolization performance determined using an Andersen Cascade Impactor analysis. A high-performance liquid chromatography method was used for measuring the salbutamol drug content. The in vivo pharmacodynamics of the formulations was monitored in 12 healthy and 12 asthmatic volunteers.Results: The percentage of the fine particle fractions (FPF) for formulations 1, 2, and 3 were 24.87±0.52%, 33.82±3.80%, and 41.50±2.86%, respectively. The mass median aerodynamic diameters (MMAD) were around 3 μm for all formulations. The pharmacodynamic parameters, forced vital capacity (FVC), forced expiratory volume in one second (FEVConclusion: The formulations of salbutamol dry powder aerosols with a fine lactose carrier produced a high deposition in the lower regions of the respiratory tract. Although the FEF


2001 ◽  
Vol 120 (5) ◽  
pp. A316-A317
Author(s):  
P MAERTEN ◽  
S COLPAERT ◽  
Z LIU ◽  
K GEBOES ◽  
J CEUPPENS ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document